AgenciesEris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 7871.82 Crore) operating in Pharmaceuticals sector.
Eris Lifesciences key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2022.
Financials
For the quarter ended 31-12-2022, the company has reported a Consolidated Total Income of Rs 425.50 Crore, down -8.63 % from last quarter Total Income of Rs 465.68 Crore and up 26.13 % from last year same quarter Total Income of Rs 337.34 Crore. Company has reported net profit after tax of Rs 100.23 Crore in latest quarter.
The company’s top management includes Mr.Amit Bakshi, Mr.Krishnakumar Vaidyanathan, Mr.Inderjeet Singh Negi, Mr.Kaushal Shah, Mr.Rajeev Dalal, Mr.Vasudevan Sujesh, Ms.Kalpana Unadkat, Mr.Prashant Gupta. Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-12-2022, the company has a total of 14 Crore shares outstanding.
The brokerage expects 16% earnings CAGR over FY23-25, led by niche launches/line extensions across therapies of cardio-metabolic, dermatology, CNS, and women’s health. ERIS is broadening its growth levers across major therapies, supported with MR addition and increasing reach. The valuation remains attractive at 16x/15xFY24E/FY25E EPS of INR36.5/INR37.8.
Promoter/FII Holdings
Promoters held 52.7 per cent stake in the company as of 31-Dec-2022, while FIIs owned 15.5 per cent, DIIs 9.95 per cent.
Friday, 17 Mar, 2023- Front Page
- Pure Politics
- ET Markets
- Smart Investing
- More
RBI Keeps Close Watch on Credit Suisse CrisisThe Reserve Bank of India (RBI) is monitoring developments related to Credit Suisse, though the Swiss lender’s limited size and scope in the country means that any major impact is unlikely, said people familiar with the matter. Local bond traders said the risk of contagion is negligible. Bankers said Credit Suisse India will have enough capital.
Vinod Adani Part of Promoter Group: Adani Group to BoursesThe Adani Group said Vinod Adani continues to be a part of the promoter group, in a stock exchange filing on Thursday.
After Notices, e-Pharmacies Look to Make a Case to GovtOver a dozen online pharmacies are seeking an audience with health ministry officials to explain their stance over show-cause notices issued to them last month over sale of drugs in alleged violation of norms, top executives said.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Get Unlimited Access to The Economic Times 
